Current State of Monoclonal Antibody Therapy for Allergic Diseases

Chen, Yan; Wang, Wei; Yuan, Huatang; Li, Yan; Lv, Zhe; Cui, Ye; Liu, Jie; Ying, Sun

doi:10.1016/j.eng.2020.06.029

Cited by 10 publications

(6 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the pathogenesis of AR, type 2 immunity plays an important role [4]. Thus, type 2 cytokines, such as IL-4, IL-5, and IL-13, are promising therapeutical targets for AR and also other allergic diseases, such as asthma and atopic dermatitis [7,9]. Unfortunately, according to our literature review, there were currently no RCTs investigating the safety of anti-IL-5/5Ra mAbs including mepolizumab, reslizumab and benralizumab, or anti-IL-13 mAbs including lebrikizumab and tralokinumab in AR.…”

Section: Discussionmentioning

confidence: 99%

“…Given traditional treatment regimens are not always efficacious, there is certainly a role for newer therapies, such as monoclonal antibodies (mAbs) [6]. As the progress of researches on the immunopathogenic mechanisms of AR, mAbs blocking essential disease-causing factors are proven to have promising therapeutic effects [7][8][9][10][11][12]. However, the overall safety of mAbs is still in question, with a poorly understanding of the underlying mechanisms of many mAb-related adverse reactions [13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adverse Events for Monoclonal Antibodies in Patients with Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Lin

Wang

Zhu

et al. 2023

JCM

View full text Add to dashboard Cite

(1) Background: Allergic rhinitis (AR) is a common disease in otolaryngology and novel biological therapies are required for clinical needs. To assess the tolerability of monoclonal antibodies, justifying their clinical applications, we presented a comprehensive safety profile of biologics in AR; (2) Methods: A systematic literature search was conducted following PRISMA guidelines for randomized clinical trials comparing monoclonal antibodies and placebo in AR. PubMed, Web of Science, Medline, and Cochrane were searched up until 9 January 2023. Among 3590 records in total, 12 studies with more than 2600 patients were included. Quality was assessed for all studies using Cochrane risk-of-bias tool for randomized trials, and subgrouped meta-analysis was performed; (3) Results: We accomplished an up-to-date literature overview and analysis on adverse events of monoclonal antibodies in AR. Total, common, severe, discontinuation-causing, and serious adverse events failed to reach statistical significance. Country was an essential factor for heterogeneity, and urticaria was the adverse event at highest risk (RR 2.81, 95% CI 0.79–9.95); (4) Conclusions: Monoclonal antibodies are considered well tolerated and relatively safe in patients with AR. The regions of patients and hypersensitive adverse reactions such as urticaria require a special caution in biological treatments in AR.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Adverse Events for Monoclonal Antibodies in Patients with Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Lin

Wang

Zhu

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…It is known that, with insight into the immune mechanism, many targeted drugs are now applied to treat moderate and severe allergic diseases. As Th2A cells are pathogenic for allergic diseases, relative monoclonal antibodies are widely used, such as IL-4 monoclonal antibody (Pitrakinra, Dupilumab) ( 95 – 97 ), IL-5 monoclonal antibody (Mepolizumab, Reslizumab, Benralizumab) ( 98 ), IL-9 monoclonal antibody (MEDI-528) ( 99 ), IL-13 monoclonal antibody (Lebrikizumab, Tralokinumab) ( 100 , 101 ), IL-33 monoclonal antibody (Etokimab, AMG 282) ( 102 , 103 ), TSLP monoclonal antibody (Tezepelumab) ( 104 ), and IgE monoclonal antibody (Omalizumab, Ligelizumab) ( 105 , 106 ). Importantly, JAK can regulate the full activation of Th2A cells, thus, JAK inhibitors also play an indispensable role in allergic disease treatment ( 107 – 114 ) ( Table 1 ).…”

Section: Immunotherapy Targeting Th2a Cellsmentioning

confidence: 99%

Th2A cells: The pathogenic players in allergic diseases

Huang

Chu²,

Chen³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Proallergic type 2 helper T (Th2A) cells are a subset of memory Th2 cells confined to atopic individuals, and they include all the allergen-specific Th2 cells. Recently, many studies have shown that Th2A cells characterized by CD3+ CD4+ HPGDS+ CRTH2+ CD161high ST2high CD49dhigh CD27low play a crucial role in allergic diseases, such as atopic dermatitis (AD), food allergy (FA), allergic rhinitis (AR), asthma, and eosinophilic esophagitis (EoE). In this review, we summarize the discovery, biomarkers, and biological properties of Th2A cells to gain new insights into the pathogenesis of allergic diseases.

show abstract

“…Ligelizumab and quilizumab are other anti-IgE mAbs, mainly investigated as treatments for chronic spontaneous urticaria. Actually no trials for ligelizumab in rhinologic diseases have been yet initiated, while the evaluation of quilizumab efficacy in patients with allergic rhinitis is still in its early stages ( Table 1 ) ( 23 ).…”

Section: Pharmacological Innovationmentioning

confidence: 99%

Pharmacological, Technological, and Digital Innovative Aspects in Rhinology

et al. 2021

View full text Add to dashboard Cite

Innovation refers to the introduction of a product, a process, a service or a solution resulting in something new or significantly improved compared to the already available alternatives. In the clinical context, it is strictly related to the identification of a new added value in terms of quality, therapeutic efficacy and safety. Over the years several innovative approaches have been introduced in the clinical practice, revolutionizing the treatment and the management of important rhinologic conditions. Innovative tools, including new drugs, biomaterials, and mobile applications seem to be able to improve the clinical outcomes and the quality of life of many patients affected by (often relapsing) rhinologic diseases. Among the main modern pharmacological innovations, mention must be made of the biological drugs like monoclonal antibodies (mAbs). Recently, new mAbs have been introduced and investigated as useful arms in the treatment of some inflammatory/infectious or oncological diseases affecting the nasal cavities and paranasal sinuses. The already approved or still investigated mAbs work inhibiting different type 2 inflammation pathways, including those mediated by IgE (omalizumab), IL-4/IL-13 (dupilumab), and IL-5 (mepolizumab). Moreover, considering the higher expression of PD-L1 in nasopharyngeal carcinoma, the use of PD-1 inhibitors, such as nivolumab, or a dual CTLA-4/PD-1 blockade (ipilimumab plus nivolumab) appear to be an effective strategy for the treatment of this cancer form. The implants with bio-absorbable biomaterials represent new interesting available technological innovations. Moreover, advanced technologies such as the artificial intelligence, the machine learning as well as the augmented or virtual reality have also proved useful in rhinologic field with main impacts on precision medicine and surgery. Finally, the development and use of mobile-Health tools represent a winning strategy in monitoring of the therapy success, safety and tolerability as well as the progress of chronic disease including chronic rhinosinusitis with nasal polyps. Supporting the research of innovative tools and strategies (including pharmacological, technologic, or digital ones) is essential to improve the management of chronic diseases that significantly affect the patients' quality of life.

show abstract

Current State of Monoclonal Antibody Therapy for Allergic Diseases

Cited by 10 publications

References 53 publications

Adverse Events for Monoclonal Antibodies in Patients with Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Adverse Events for Monoclonal Antibodies in Patients with Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Th2A cells: The pathogenic players in allergic diseases

Pharmacological, Technological, and Digital Innovative Aspects in Rhinology

Contact Info

Product

Resources

About